Media stories about Alexza Pharmaceuticals (NASDAQ:ALXA) have trended somewhat positive on Thursday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexza Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news articles about the healthcare company an impact score of 44.2830574080278 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
COPYRIGHT VIOLATION WARNING: “Alexza Pharmaceuticals (ALXA) Earns Daily Coverage Optimism Rating of 0.06” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/09/21/alexza-pharmaceuticals-alxa-earns-daily-coverage-optimism-rating-of-0-06.html.
Alexza Pharmaceuticals Company Profile
Alexza Pharmaceuticals, Inc is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep.
Receive News & Ratings for Alexza Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexza Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.